



September 4, 2008

LifeVantage Corporation Invited to Present at EdgeWater Research Small/Micro Cap Conference September 24th and 25th, 2008

[LifeVantage Corporation \(OTCBB: LFVN\)](#), the maker of [Protandim®](#), the only product clinically proven to slow the progressive rate of aging, today announced that the senior management team has been invited to present at the upcoming [EdgeWater Research](#) Fall 2008 Small/Micro Cap Conference to be held in Coeur d' Alene, Idaho, on September 24th and 25th, 2008.

LifeVantage was featured in the August edition of *The EdgeWater Micro Monthly*, in which the editor David Lavigne wrote, "They have in a few months restructured a number of things (distribution - both domestic and international, etc.), embarked on adding some new product lines, skin care for example, which I think has enormous potential, and have begun to lay the ground work for entrees into other verticals, veterinary might be an example."

David Brown, LifeVantage President and CEO, said, "LifeVantage is pleased to be invited to present at the well-known EdgeWater Research Conference. This is an excellent opportunity to share the LifeVantage story with members of the financial community who are active in the Small/Micro Cap markets. LifeVantage has recently increased sales distribution, as well as its on-line presence, and has made great progress in improving overall brand awareness. Our branding efforts, together with the many scientific studies underway nationwide at leading universities and research institutes to study the effect of Protandim on various diseases and health conditions, should generate greater interest in the Company."

[About EdgeWater Research Partners, LLC](#)

EdgeWater Research Partners, LLC is an independent micro cap equities research company representing the research of David Lavigne. EdgeWater follows a number of undiscovered small and micro cap stocks through both individual research and its monthly publication, *The EdgeWater Micro Monthly*. EdgeWater's research is distributed to its subscriber base, and is also available on a piece by piece basis on the Company's website, <http://www.edgewaterresearch.com>.

[About Protandim®](#)

Protandim® is a groundbreaking, clinically proven solution for healthy aging. This patented anti-oxidant therapy is 1000's of times more powerful than red wine, oranges, blueberries, acai juice or other popular anti-oxidant supplements. Protandim works by increasing the body's natural anti-oxidant protection at the cellular level, triggering cells to produce naturally occurring protective antioxidant enzymes such as super oxide dismutase (SOD), catalase, and glutathione.

A peer-reviewed scientific study shows that after 30 days of taking Protandim, free radicals decreased an average of 40 percent, slowing the progressive aging factors to the level of a 20 year old. Protandim is currently the subject of over 20 scientific studies at leading universities and research institutes. For more information, please visit the Protandim® product web site at www.protandim.com or contact Jan Strode at 619-890-4040.

[About LifeVantage Corporation](#)

LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, natural products company, dedicated to helping people reach their health and wellness goals through science-based solutions to oxidative stress. Founded in 2003 and based in Colorado, LifeVantage develops nutraceutical products, including [Protandim](#), that leverage the company's expertise and that are intended to deliver significant health benefits to consumers. For more information, visit www.lifevantage.com or contact Jan Strode at 619-890-4040.

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company uses the words "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "predict," "project," "plan," "target" and similar terms and phrases, including references to assumptions, to identify forward-looking statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the risk that government regulators and regulations could adversely affect our business; future laws or regulations may hinder or prohibit

the production or sale of our existing product and any future products; unfavorable publicity could materially hurt our business; and the Company's ability to protect our intellectual property rights and the value of our product. These and other risk factors are discussed in greater detail in the Company's Annual Report on Form 10-KSB under the caption "Risk Factors", and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

**These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.*

Note to Editors: Contact Jan Strode at 619-890-4040 for interviews, photography, and other requests.

LifeVantage Corporation
Jan Strode, 619-890-4040
Jean Golden, 612-385-2324